Drugs / KAI-9531
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07044401 | Jul → Nov 2025 | — | Kailera | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07458269 | Mar 2026 → May 2027 expected | obesity disorder | Kailera | Active not recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07709910 | Jul 2026 → Nov 2028 expected | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07284901 | Jan 2026 → Mar 2028 expected | obesity disorder | Kailera | Recruiting | No outcome recorded |
| Phase 3 | NCT07284979 | Dec 2025 → Mar 2028 expected | obesity disorder | Kailera | Recruiting | No outcome recorded |
| Phase 3 | NCT07284875 | Dec 2025 → Feb 2028 expected | obesity disorder | Kailera | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAI-9531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284875 ↗ |
| Known as | Ribupatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07458269 ↗ |
| Route | Subcutaneous | “KAI-9531 subcutaneous (SC) injection” NCT07044401 ↗ |